SecurityWAC / Walter Investment Management Corp. (93317W102)
Institutional Owners82 (40 N-Q Owners)
Institutional Shares20,513,987 - 54.89% (ex. N-Q)
Common Shares Outstanding37,373,551 shares (as of 2017-09-30)
Institutional Value$ 5,360,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

Walter Investment Management Corp. (NYSE:WAC) has 82 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20,513,987 shares. Largest shareholders include Cooperman Leon G, First Pacific Advisors, LLC, Baker Street Capital Management, LLC, Birch Run Capital Advisors, LP, Lion Point Capital, LP, Centerbridge Partners, L.P., Deer Park Road Management Company, LP, Arrowgrass Capital Partners (us) Lp, Oaktree Capital Management LP, and Weiss Multi-Strategy Advisers LLC.

Walter Investment Management Corp. (NYSE:WAC) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.


File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-01-10 13F-HR SIMPLEX TRADING, LLC Call 15 0 -100.00 0 0
2017-11-15 13F-HR CQS Cayman LP 200,000 0 -100.00 189 0 -100.00
2018-02-14 13F-HR NORTHERN TRUST CORP 94,883 30,197 -68.17 57 25 -56.14
2017-12-29 N-Q Nuveen Senior Income Fund (see advisory)
2018-01-25 N-Q Columbia Funds Series Trust (see advisory)
2018-02-09 13F-HR AMERICAN INTERNATIONAL GROUP INC 413 413 0.00 0 0
2017-10-27 N-Q Eaton Vance Floating-rate Income Plus Fund (see advisory)
2017-10-27 N-Q Virtus Total Return Fund Inc. (see advisory)
2018-02-14 13F-HR WOLVERINE TRADING, LLC 12,903 0 -100.00 8 0 -100.00
2017-12-29 N-Q Nuveen Floating Rate Income Fund (see advisory)
2018-03-01 N-Q Eaton Vance Ltd Duration Income Fund (see advisory)
2018-03-12 SC 13G Oaktree Capital Management LP 962,455
2018-02-27 13F-HR Advisornet Financial, Inc 2,512 2
2018-02-13 SC 13G/A NEW SOUTH CAPITAL MANAGEMENT INC 3,169,503 0 -100.00
2017-12-29 N-Q Nuveen Floating Rate Income Opportunity Fund (see advisory)
2018-02-14 13F-HR VANGUARD GROUP INC 944,421 514,261 -45.55 559 433 -22.54
2018-02-13 13F-HR GEODE CAPITAL MANAGEMENT, LLC 213,188 0 -100.00 126 0 -100.00
2018-02-28 13F-HR/A-1 FEDERATED INVESTORS INC /PA/ 29,853 23,680 -20.68 18 20 11.11
2018-02-14 13F-HR Ameritas Investment Partners, Inc. 3,297 3,297 0.00 1 8 700.00
2018-02-12 13F-HR CITIGROUP INC 4,700 0 -100.00 3 0 -100.00
2017-11-29 N-Q Virtus Variable Insurance Trust (see advisory)
2018-02-14 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 550,000 550,000 0.00 326 464 42.33
2018-02-13 SC 13D/A Birch Run Capital Advisors, LP 7,474,939 1,753,649 -76.54
2018-02-27 N-Q Blackstone Alternative Investment Funds (see advisory)
2018-02-21 SC 13G Phoenix Investment Adviser LLC 691,920
2017-12-29 N-Q Nuveen Short Duration Credit Opportunities Fund (see advisory)
2018-01-26 N-Q Fidelity Concord Street Trust (see advisory)
2017-12-29 N-Q Virtus Etf Trust Ii (see advisory)
2018-02-14 13F-HR Advisor Group, Inc. 10 10 0.00 0 0
2018-02-28 N-Q Virtus Opportunities Trust (see advisory)
2018-02-21 SC 13D First Pacific Advisors, LLC 1,414,323 2,416,851 70.88
2018-02-14 13F-HR WOLVERINE TRADING, LLC Put 12,200 0 -100.00 7 0 -100.00
2018-03-06 SC 13G Cqs (us), Llc 677,690
2018-02-14 13F-HR UBS Group AG 3,000 162,068 5,302.27 2 136 6,700.00
2017-11-28 N-Q Tri-continental Corp (see advisory)
2017-10-27 N-Q Virtus Global Multi-sector Income Fund (see advisory)
2018-02-14 13F-HR Centerbridge Partners, L.P. 1,096,787 1,096,787 0.00 649 924 42.37
2017-12-29 N-Q Palmer Square Opportunistic Income Fund (see advisory)
2017-11-14 13F-HR Paloma Partners Management Co 71,100 0 -100.00 67 0 -100.00
2018-02-28 N-Q Advisors Series Trust (see advisory)
2018-02-06 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 541,879 305,100 -43.70 321 257 -19.94
2018-01-17 13F-HR Cutler Group LP 4,864 23,200 376.97 2 19 850.00
2018-01-10 13F-HR SIMPLEX TRADING, LLC Put 1 0 -100.00 0 0
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 12,500 0 -100.00 7 0 -100.00
2018-02-14 13F-HR Weiss Multi-Strategy Advisers LLC 735,000 735,000 0.00 435 619 42.30
2018-03-01 N-Q Nuveen Investment Trust Iii (see advisory)
2017-11-29 N-Q Vanguard Institutional Index Funds (see advisory)
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 14,588 11,064 -24.16 9 9 0.00
2018-02-14 13F-HR Invesco Ltd. 284,399 288,463 1.43 168 243 44.64
2018-02-15 13F-HR/A-1 Alta Fundamental Advisers LLC 250,000 0 -100.00 148 0 -100.00
2017-12-29 N-Q Nuveen Credit Strategies Income Fund (see advisory)
2018-02-09 13F-HR Virtu Financial LLC 35,979 30
2018-02-14 13F-HR GOLDMAN SACHS GROUP INC 0 18,768 0 16
2017-11-29 N-Q Eaton Vance Variable Trust (see advisory)
2018-03-08 SC 13G Deer Park Road Management Company, LP 997,480
2018-02-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 16,168 0 -100.00 10 0 -100.00
2018-02-14 SC 13G/A Raging Capital Management, LLC 2,544,204 0 -100.00
2017-11-28 N-Q Highland Funds I (see advisory)
2018-02-20 SC 13D COOPERMAN LEON G 3,738,676
2018-02-02 13F-HR MEEDER ASSET MANAGEMENT INC 2,692 2,439 -9.40 2 2 0.00
2017-10-27 N-Q Eaton Vance Floating-rate Income Trust (see advisory)
2017-11-28 N-Q Highland Floating Rate Opportunities Fund (see advisory)
2017-11-14 13F-HR GROUP ONE TRADING, L.P. 20,018 0 -100.00 19 0 -100.00
2018-02-14 13F-HR DEUTSCHE BANK AG\ 2,657 165 -93.79 1 0 -100.00
2018-02-09 13F-HR BlackRock Inc. 626,353 35,795 -94.29 371 30 -91.91
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 239,597 65,778 -72.55 142 55 -61.27
2018-04-10 SC 13G/A CANYON CAPITAL ADVISORS LLC 1,027,416 291,576 -71.62
2018-01-17 13F-HR Cutler Group LP Call 2,500 0 -100.00 0 0
2018-02-14 13F-HR ROYAL BANK OF CANADA 1,000 0 -100.00 1 0 -100.00
2018-02-14 13F-HR STATE STREET CORP 30,774 24,927 -19.00 18 21 16.67
2018-03-01 N-Q City National Rochdale Funds (see advisory)
2018-02-02 13F-HR TELEMUS CAPITAL, LLC 0 198,365 0 167
2017-11-20 13F-HR GSA CAPITAL PARTNERS LLP 265,974 0 -100.00 252 0 -100.00
2017-11-14 13F-HR Tower Research Capital LLC (TRC) 27,035 0 -100.00 26 0 -100.00
2018-02-14 13F-HR Squarepoint Ops LLC 120,817 0 -100.00 72 0 -100.00
2018-02-28 N-Q Sunamerica Income Funds (see advisory)
2018-01-10 13F-HR SIMPLEX TRADING, LLC 1,388 0 -100.00 0 0
2018-03-01 N-Q Sei Institutional Managed Trust (see advisory)
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 20 0 -100.00 0 0
2017-11-08 13F-HR BRIGHTON JONES LLC 21,505 0 -100.00 20 0 -100.00
2018-02-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 500 0 -100.00 0 0
2017-11-13 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 152,551 0 -100.00 144 0 -100.00
2017-11-29 N-Q Fpa Funds Trust (see advisory)
2018-02-09 13F-HR Bank of New York Mellon Corp 41,027 0 -100.00 24 0 -100.00
2018-02-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 45,137 0 -100.00 27 0 -100.00
2017-11-13 13F-HR PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. 83,527 0 -100.00 79 0 -100.00
2018-02-14 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 0 37 0 0
2018-01-17 13F-HR Edge Wealth Management LLC 66,940 0 -100.00 40 0 -100.00
2017-11-28 N-Q NexPoint Credit Strategies Fund (see advisory)
2018-02-14 13F-HR D. E. Shaw & Co., Inc. 65,773 0 -100.00 39 0 -100.00
2018-02-14 13F-HR BARCLAYS PLC Put 0 92,000 0 78
2017-11-13 13F-HR/A-1 NORGES BANK 240,911 240,911 0.00 665 934 40.45
2018-02-20 SC 13D Lion Point Capital, LP 1,443,687
2018-01-17 13F-HR Cutler Group LP Put 600 600 0.00 1 1 0.00
2018-02-28 N-Q Highland Funds Ii (see advisory)
2018-02-13 SC 13G/A GoodHaven Capital Management, LLC 1,823,063 0 -100.00
2017-11-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,023 0 -100.00 1 0 -100.00
2018-02-28 N-Q Virtus Equity Trust (see advisory)
2018-03-05 13F-HR/A-1 BNP PARIBAS ARBITRAGE, SA 1,603 0 -100.00 946 0 -100.00
2017-11-29 N-Q Nuveen Diversified Dividend & Income Fund (see advisory)
2018-02-14 13F-HR PANAGORA ASSET MANAGEMENT INC 894 894 0.00 1 1 0.00
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 201 0 -100.00 0 0
2018-02-09 13F-HR CITADEL ADVISORS LLC 0 54,929 0 46
2017-10-30 13F-HR PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO 13,310 0 -100.00 13 0 -100.00
2017-11-29 N-Q Eaton Vance Senior Income Trust (see advisory)
2018-02-14 13F-HR MACQUARIE GROUP LTD 40,200 34
2017-11-21 N-Q Meeder Funds (see advisory)
2018-02-28 N-Q Ishares Trust (see advisory)
2018-02-14 13F-HR MORGAN STANLEY 12,031 14,841 23.36 7 13 85.71
2017-11-29 N-Q Vanguard Index Funds (see advisory)
2017-11-22 N-Q Litman Gregory Funds Trust (see advisory)
2017-11-13 13F-HR DIMENSIONAL FUND ADVISORS LP 27,045 0 -100.00 26 0 -100.00
2017-11-09 13F-HR LMR Partners LLP 80,916 0 -100.00 77 0 -100.00
2017-11-14 13F-HR PACIFIC ALTERNATIVE ASSET MANAGEMENT COMPANY, LLC 81,900 56,400 -31.14 78 33 -57.69
2018-02-14 13F-HR BARCLAYS PLC 81 81 0.00 0 0
2018-03-01 N-Q Rivernorth Funds (see advisory)
2018-02-14 13F-HR ARROWGRASS CAPITAL PARTNERS (US) LP 971,404 971,404 0.00 575 819 42.43
2017-11-29 N-Q Vanguard Valley Forge Funds (see advisory)
2018-02-14 SC 13D/A Baker Street Capital Management, LLC 8,677,524 2,032,038 -76.58
2017-11-29 N-Q Nuveen Credit Opportunities 2022 Target Term Fund (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( WAC / Walter Investment Management Corp. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 93317W102